Gilgamesh Pharma
Novel psychiatric therapeutics targeting neurobiological mechanisms of mental illness, including rapid-acting treatments for depression, anxiety, opioid use disorder, PTSD, and traumatic brain injury
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2025
- Latest Form D
- $2.3M, Mar 2026
- Total capital
- $68.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $68.3M
- 4 Form D · last Mar 2026
- 7 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$2.3M
- Private capital raisedForm D · SEC · 3rd filing$60M
- Offering registeredForm D · SEC · 2nd filing$4.4M
- Private capital raisedForm D · SEC · 1st filing$6.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Amy KruseDirectorNamed in SEC Form D filings
- Andrew KruegelExecutive Officer, DirectorNamed in SEC Form D filings
- Jonathan SpornExecutive Officer, DirectorNamed in SEC Form D filings
- Phil SkolnickDirectorNamed in SEC Form D filings
- Robert BermanDirectorNamed in SEC Form D filings
- Zia HuqueDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 4- PendingNovel Ergolines And Methods Of Treating Mood DisordersUSPTOApplication 19481305
- PendingMethods Of Treating Psychiatric Disorders Or Pain Using (R)-2-(4-FLUOROPHENYL)-2-(METHYLAMINO)CYCLOHEXAN-1-ONE Or Pharmaceutically Acceptable Salts ThereofUSPTOApplication 19588020
- PendingCrystalline Salts Of 2-PHENYL-2-AMINOCYCLOHEXAN-1-ONE DerivativesUSPTOApplication 19490052
Show all 4 patent records
- Novel Ergolines And Methods Of Treating Mood DisordersApplication 19481305Pending
- Methods Of Treating Psychiatric Disorders Or Pain Using (R)-2-(4-FLUOROPHENYL)-2-(METHYLAMINO)CYCLOHEXAN-1-ONE Or Pharmaceutically Acceptable Salts ThereofApplication 19588020Pending
- Crystalline Salts Of 2-PHENYL-2-AMINOCYCLOHEXAN-1-ONE DerivativesApplication 19490052Pending
- Pyridine Derivatives For Treating Psychiatric DisordersApplication 19579029Pending
Related companies, and why
- ESTRIGENIX THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Kyverna TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Liminal BioSciences Inc.Similar federal contract value in Biotech · null in contracts
- Ernexa Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- KAZIA THERAPEUTICS LTDSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .